Personalised Immunotherapy in Sepsis:
a precision medicine approach

Picking up wind - EU Research Project ImmunoSep kicks off

Defying the gale-force winds and heavy rain of storm ‘Sabine’, the multinational ImmunoSep consortium came together in Nijmegen, The Netherlands, to successfully kick-off the new research project ImmunoSep.

Its main aim is to advance personalised immunotherapy in sepsis, which provides hope for reducing mortality in sepsis patients. The project, an international collaboration of 14 partners, explores the usefulness of precision medicine to treat this life-threatening condition while also paving the way for further on-going research in this field. Coordinated by the Radboud University Medical Center, Nijmegen, the Netherlands, the project will receive just over EUR 10 million funding from the European Union’s Horizon 2020 Framework Programme over the next four years.

Prof. Giamarellos from the National and Kapodistrian University of Athens notes: “We want to open a new way of treating severe infection through personalised treatment with the potential to represent a qualitative leap in sepsis outcome and to provide a basis for future precision-medicine in immune-based disorders. To this end, the consortium is uniquely placed to achieve this goal. The ImmunoSep project partners are world recognised experts in cutting-edge methodologies, the innovation potential of the study results is high and a first pilot study of personalised immunotherapy in sepsis performed by two of the project partners is going to provide invaluable experience to the whole ImmunoSep research team.”